Antimicrobial and antibiofilm activity of secondary metabolites of lichens against methicillin-resistant Staphylococcus aureus strains from cystic fibrosis patients

Future Microbiology

Volumn 8, Issue 2, 2013, Pages 281-292

  Pompilio, Arianna ^a   Pomponio, Stefano ^a   Di Vincenzo, Valentina ^a   Crocetta, Valentina ^a   Nicoletti, Marcello ^b   Piovano, Marisa ^c   Garbarino, Juan A ^c   Di Bonaventura, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c DEPARTAMENTO DE FÍSICA   (Chile)

Author keywords

antibiotic resistance; biofilm; cystic fibrosis; lung infection; secondary metabolites of lichens; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; ATRANORIN; FUMARPROTOCETRACIC ACID; POLYSTYRENE; UNCLASSIFIED DRUG; USNIC ACID;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOFILM; BROTH DILUTION; CYSTIC FIBROSIS; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; LICHEN (ORGANISM); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PLANKTON; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ANTI-BACTERIAL AGENTS; BENZOFURANS; BIOFILMS; BIOLOGICAL PRODUCTS; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; FUMARATES; HUMANS; HYDROXYBENZOATES; LICHENS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PLANT EXTRACTS; STAPHYLOCOCCAL INFECTIONS;

EID: 84873332935     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.142     Document Type: Article

References (47)

1. Cystic Fibrosis Foundation Patient Registry. 2008 Annual Data Report. Cystic Fibrosis Foundation, MD, USA (2009).
2. de Vrankrijker AM, Wolfs TF, van der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatr. Respir. Rev. 11, 246-254 (2010).
3. Goodrich JS, Sutton-Shields TN, Kerr A, Wedd JP, Miller MB, Gilligan PH Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J. Clin. Microbiol. 47(4), 1231-1233 (2009).
4. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(8), 814-821 (2008).
5. Oliver A, Mena A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin. Microbiol. Infect. 16(7), 798-808 (2010).
6. Pompilio A, Pomponio S, Crocetta V et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol. 11, 159 (2011).
7. Kahl BC, Duebbers A, Lubritz G et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J. Clin. Microbiol. 41, 4424Y 4427 (2003). (Pubitemid 37099721)
8. Goerke C, Wolz C. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int. J. Med. Microbiol. 300(8), 520-525 (2010).
9. Molina A, Del Campo R, Máiz L, Morosini MI, Lamas A, Baquero F. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J. Antimicrob. Chemother. 62, 961-967 (2008).
10. Gibbons S. Phytochemicals for bacterial resistance: strengths, weaknesses and opportunities. Planta Med. 74, 594-602 (2008). (Pubitemid 351846775)
11. Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
12. Wright GD, Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol. Med. 13, 260-267 (2007). (Pubitemid 46836873)
13. Hunek S. The significance of lichens and their metabolites. Naturwissenschaften 86, 559-570 (1999).
14. Lautwerwein M, Oethinger M, Belsner K, Peters T, Marre R. In vitro activities of the lichen secondary metabolites vulpinic acid, (+)-usnic acid, and (-)-usnic acid against aerobic and anaerobic microorganisms. Antimicrob. Agents Chemother. 39, 2541-2543 (1995).
15. Ingòlfsdòttir K. Usnic acid. Phytochemistry 61, 729-736 (2002).
16. Francolini I, Norris P, Piozzi A, Donelli G, Stoodley P. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob. Agents Chemother. 48(11), 4360-4365 (2004). (Pubitemid 39434899)
17. Segatore B, Bellio P, Setacci D et al. In vitro interaction of usnic acid in combination with antimicrobial agents against methicillin-resistant Staphylococcus aureus clinical isolates determined by FICI and DE model methods. Phytomedicine 19(3-4), 341-347 (2012).
18. Elo H, Matikainen J, Pelttari E. Potent activity of the lichen antibiotic (+)-usnic acid against clinical isolates of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Naturwissenschaften 94(6), 465-468 (2007). (Pubitemid 46742063)
19. Celenza G, Segatore B, Setacci D et al. In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates. Phytomedicine 19(7), 596-602 (2012).
20. Pompilio A, Crocetta V, Scocchi M et al. Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and antibiofilm activity of natural and designed a-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol. 12, 145 (2012).
21. Strommenger B, Kettlitz C, Werner G, Witte W. Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in Staphylococcus aureus. J. Clin. Microbiol. 41, 4089-4094 (2003). (Pubitemid 37099669)
22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, M100-S20. Clinical and Laboratory Standards Institute, PA, USA (2010).
23. Stepanović S, Vuković D, Hola V et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 115(8), 891-899 (2007). (Pubitemid 47260470)
24. Hucker GJ. A new modification and application of the Gram stain. J. Bacteriol. 6(4), 395-397 (1921).
25. Ren CL, Morgan WJ, Konstan MW et al. Presence of methicillin-resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr. Pulmonol. 42, 513-518 (2007). (Pubitemid 46870382)
26. Molnár K, Farkas E. Current results on biological activities of lichen secondary metabolites: A review. Z. Naturforsch. C. 65(3-4), 157-173 (2010).
27. Paudel B, Bhattarai HD, Lee HK, Oh H, Shin HW, Yim JH. Antibacterial activities of Ramalin, usnic acid and its three derivatives isolated from the Antarctic lichen Ramalina terebrata. Z. Naturforsch. C. 65, 34-38 (2010).
28. Honda NK, Pavan FR, Coelho RG et al. Antimycobacterial activity of lichen substances. Phytomedicine 17(5), 328-332 (2010).
29. Türk H, Yilmaz M, Tay T, Türk AO, Kivanç M. Antimicrobial activity of extracts of chemical races of the lichen Pseudevernia furfuracea and their physodic acid, chloroatranorin, atranorin, and olivetoric acid constituents. Z. Naturforsch. C. 61(7-8), 499-507 (2006). (Pubitemid 44367443)
30. Bugni TS, Andjelic CD, Pole AR, Rai P, Ireland CM, Barrows LR. Biologically active components of a Papua New Guinea analgesic and anti-inflammatory lichen preparation. Fitoterapia 80(5), 270-273 (2009).
31. Yilmaz M, Türk AO, Tay T, Kivanç M. The antimicrobial activity of extracts of the lichen Cladonia foliacea and its (-)-usnic acid, atranorin, and fumarprotocetraric acid constituents. Z. Naturforsch C. 59(3-4), 249-254 (2004). (Pubitemid 38497884)
32. Freysdottir J, Omarsdottir S, Ingólfsdóttir K, Vikingsson A, Olafsdottir ES. In vitro and in vivo immunomodulating effects of traditionally prepared extract and purified compounds from Cetraria islandica. Int. Immunopharmacol. 8(3), 423-430 (2008).
33. Ghione M, Parrello D, Grasso L. Usnic acid revisited, its activity on oral flora. Chemioterapia 7, 302-305 (1988). (Pubitemid 18266762)
34. Bjarnsholt T, Jensen PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44, 547-558 (2009).
35. Caraher E, Reynolds G, Murphy P, McClean S, Callaghan M. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 26, 213-216 (2007).
36. Di Bonaventura G, Prosseda G, Del Chierico F et al. Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis. Int. J. Immunopathol. Pharmacol. 20, 529-537 (2007). (Pubitemid 47531056)
37. Pompilio A, Crocetta V, Confalone P et al. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10, 102 (2010).
38. Silva IN, Ferreira AS, Becker JD et al Mucoid morphotype variation of Burkholderia multivorans during chronic cystic fibrosis lung infection is correlated with changes in metabolism, motility, biofilm formation and virulence. Microbiology 157(Pt 11), 3124-3137 (2011).
39. Manago K, Nishi J, Wakimoto N. Biofilm formation by and accessory gene regulator typing of methicillin-resistant Staphylococcus aureus strains recovered from patients with nosocomial infections. Infect. Control Hosp. Epidemiol. 27, 188-190 (2006). (Pubitemid 43384767)
40. Kim S, Greenleaf R, Miller MC et al. Mechanical effects, antimicrobial efficacy and cytotoxicity of usnic acid as a biofilm prophylaxis in PMMA. J. Mater. Sci. Mater. Med. 22(12), 2773-2780 (2011).
41. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109, 317-325 (2002). (Pubitemid 34141805)
42. Song Y, Salinas D, Nielson DW, Verkman AS. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am. J. Physiol. Cell. Physiol. 290, C741-C749 (2006).
43. Brisdelli F, Perilli M, Sellitri D et al. Cytotoxic activity and antioxidant capacity of purified lichen metabolites: An in vitro study. Phytother. Res. doi:10.1002/ptr.4739 (2012) (Epub ahead of print).
44. Krishna DR, Venkataramana D. Pharmacokinetics of d-usnic acid after intravenous and oral administration. Drug Metab. Dispos. 20, 909-911 (1992).
45. Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol. 23(3), 366-373 (2008). (Pubitemid 351342073)
46. Pramyothin P, Janthasoot W, Pongnimitprasert N, Phrukudom S, Ruangrungsi N. Hepatotoxic effect of (+)usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria. J. Ethnopharmacol. 90(2-3), 381-387 (2004). (Pubitemid 38180491)
47. Han D, Matsumaru K, Rettori D, Kaplowitz N. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol. 67(3), 439-451 (2004). (Pubitemid 38232884)